Van't Veer LJ - Search Results

1

The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.

Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomäki K, Pruntel R, Verhoef S, Van't Veer LJ. Ruijs MW, et al. Eur J Hum Genet. 2007 Jan;15(1):110-4. doi: 10.1038/sj.ejhg.5201715. Epub 2006 Sep 27. Eur J Hum Genet. 2007. PMID: 17003841

2

ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ. Broeks A, et al. Am J Hum Genet. 2000 Feb;66(2):494-500. doi: 10.1086/302746. Am J Hum Genet. 2000. PMID: 10677309 Free PMC article.

3

Detection of circulating breast tumor cells by differential expression of marker genes.

Bosma AJ, Weigelt B, Lambrechts AC, Verhagen OJ, Pruntel R, Hart AA, Rodenhuis S, van 't Veer LJ. Bosma AJ, et al. Clin Cancer Res. 2002 Jun;8(6):1871-7. Clin Cancer Res. 2002. PMID: 12060630

4

Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.

Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G. Hogervorst FB, et al. Cancer Res. 2003 Apr 1;63(7):1449-53. Cancer Res. 2003. PMID: 12670888

5

[Genetic research with stored human tissue: a coding procedure with optimal use of information and protection of privacy].

Schmidt MK, van Leeuwen FE, Klaren HM, Tollenaar RA, van 't Veer LJ. Schmidt MK, et al. Ned Tijdschr Geneeskd. 2004 Mar 20;148(12):564-8. Ned Tijdschr Geneeskd. 2004. PMID: 15074178 Review. Dutch.

6

Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations.

van Beers EH, van Welsem T, Wessels LF, Li Y, Oldenburg RA, Devilee P, Cornelisse CJ, Verhoef S, Hogervorst FB, van't Veer LJ, Nederlof PM. van Beers EH, et al. Cancer Res. 2005 Feb 1;65(3):822-7. Cancer Res. 2005. PMID: 15705879

7

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.

van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, Van't Veer LJ, Tollenaar RA. van Sprundel TC, et al. Br J Cancer. 2005 Aug 8;93(3):287-92. doi: 10.1038/sj.bjc.6602703. Br J Cancer. 2005. PMID: 16052221 Free PMC article.

8

Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.

van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van Houwelingen JC, van't Veer LJ, Rookus MA, van Leeuwen FE; Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON). van Asperen CJ, et al. J Med Genet. 2005 Sep;42(9):711-9. doi: 10.1136/jmg.2004.028829. J Med Genet. 2005. PMID: 16141007 Free PMC article.

9

Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation.

Ruijs MW, Verhoef S, Wigbout G, Pruntel R, Floore AN, de Jong D, van T Veer LJ, Menko FH. Ruijs MW, et al. Fam Cancer. 2006;5(2):169-74. doi: 10.1007/s10689-005-4789-9. Fam Cancer. 2006. PMID: 16736287

10

Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.

Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ. Schmidt MK, et al. J Clin Oncol. 2007 Jan 1;25(1):64-9. doi: 10.1200/JCO.2006.06.3024. Epub 2006 Nov 28. J Clin Oncol. 2007. PMID: 17132695

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

391 results

Search Page